360° SearchNetwork Hot Spots Trends Time Series

Advanced Search Options >>

Pharmacyclics Inc

Type: Company

Name: Pharmacyclics Inc

First reported May 21 2013 - Updated May 21 2013 - 1 reports

FDA Food & Drug Administration

2013 FDA Drug Approval Calendar

Home » Blogs » BOSTON (TheStreet) -- Gilead Sciences and Amarin highlight the updated list of biotech and pharmaceutical companies with FDA drug approval decisions expected for the remainder of 2013.Related Biotechnology, Pharmaceutical and Healthcare ... [Published BioPortfolio - May 21 2013]

Entities: FDA Food & Drug Administration, Drugs, Amarin Corporation Plc, Biotechnology, Gilead Sciences Inc

First reported May 21 2013 - Updated May 21 2013 - 1 reports

United Therapeutics Corp

Pre-Market Analysis on STSI, IPXL, PCYC, and UTHR

NASDAQ:STSI / NASDAQ:IPXL / NASDAQ:PCYC / NASDAQ:UTHR05/21/2013 [ACCESSWIRE]StockCall.com Provides Stock Research on Star Scientific Inc., Impax Laboratories Inc., Pharmacyclics Inc., and United Therapeutics Corp.New York City, New York -- (May 21, 2 ... [Published BayStreet.ca - May 21 2013]

Entities: Pharmacyclics Inc, Impax Laboratories Inc, United Therapeutics Corp, Star Scientific Inc

First reported May 21 2013 - Updated May 21 2013 - 1 reports

Negative Day, but Strong Technicals

The stock market indices started the week out with upward movement until midsession when the S&P 500 reached just under 1673, a new all-time high, and the Nasdaq 100 reached almost 33. They came down hard in a 5-wave decline, bounced in the afternoon, ... [Published Zecco - May 21 2013]

Entities: Stocks, NASDAQ 100, S&P 500, Retracement

First reported May 20 2013 - Updated May 20 2013 - 1 reports

Pharmacyclics Earnings Review: 19 Days after Announcement Shares Up 11.3% (PCYC)

(Comtex SmarTrend(R)) 19 days ago, on May 1st, 2013, Pharmacyclics (NASDAQ:PCYC) reported its earnings. Analysts, on average, expected a loss of $0.38 per share on sales of $15.9 million. Pharmacyclics actually reported a loss of $0.73 per share on ... [Published Individual.com - May 20 2013]

Entities: Pharmacyclics Inc, Stocks, Comtex

First reported May 20 2013 - Updated May 20 2013 - 1 reports

PHARMACYCLICS - Ibrutinib - Promising to Deliver More - new market research report

Our risk-reward analysis suggests that there is meaningful upside on positive PhIII data and approval of Ibrutinib (PCI-32765, PhIII, BTK inhibitor, partnered with JNJ, PhIII, CLL/SLL/PLL, MCL; PhII, DLBCL, MM, FL) in next two years.Ibrutinib, a winner ... [Published TransWorldNews - May 20 2013]

Entities: Ibrutinib, Pharmacyclics Inc, bone marrow, Drugs

First reported May 20 2013 - Updated May 20 2013 - 2 reports

Drivers of M&A in 2013-2016: PI3Ks and BTK Inhibitors - Part I - new market research report

New targets/drugs remain an evergreen medical need to address the unmet need of drug resistance in the treatment of cancer. Large global pharma are constantly on the hunt for drugs with label expansion potential = Longevity and Blockbuster Potential! ... [Published TransWorldNews - May 20 2013]

Entities: Mergers & Acquisitions, Kinase, Curis Incorporated, Pharmacyclics Inc

First reported May 18 2013 - Updated May 18 2013 - 1 reports

Pharmacyclics Stock Rating Upgraded by RBC Capital (PCYC)

Pharmacyclics (NASDAQ: PCYC)A number of other firms have also recently commented on PCYC. Analysts at Zacks downgraded shares of Pharmacyclics to a ?neutral? rating in a research note to investors on Wednesday, May 8th. They now have a $95.00 price target ... [Published American Banking News - May 18 2013]

Entities: Pharmacyclics Inc, RBC Capital Markets, Earnings Per Share, Stocks

First reported May 16 2013 - Updated May 16 2013 - 2 reports

Molecular Diagnostics Market Expected to Grow at a CAGR of 11.42% by 2016

Dallas, TX -- (SBWIRE) -- 05/16/2013 -- RnRMarketResearch.com adds new market research report “Global Molecular Diagnostics Market 2012-2016” to its store.This new report on Global Molecular Diagnostics market forecast to grow at a CAGR of 11.42 percent ... [Published SBWire - May 16 2013]

Entities: Molecular Diagnostics, CAGR, Market

First reported May 15 2013 - Updated May 16 2013 - 1 reports

ASCO '13 Preview: Gilead's Big Cancer Debut

FOSTER CITY, Calif. (TheStreet) -- Gilead Sciences' (GILD)Results from the idelalisab study in CLL were announced Wednesday night in advance of a presentation at next month's American Society of Clinical Oncology (ASCO) annual meeting.Gilead is known ... [Published TheStreet.com - May 15 2013]

Entities: Gilead Sciences Inc, Patient, Cancer

First reported May 15 2013 - Updated May 15 2013 - 1 reports

Breakthrough Designations Reach 13

One of the outcomes of the 2012 Food and Drug Administration Safety and Innovation Act (FDASIA) was the creation of the “Breakthrough Therapy” designation. The new law allows FDA to grant a Breakthrough Therapy designation to drugs showing early clinical ... [Published I Am Biotech - May 15 2013]

Entities: FDA Food & Drug Administration, Epidermolysis Bullosa, Vertex

First reported May 15 2013 - Updated May 15 2013 - 1 reports

Corning Incorporated (GLW), Pharmacyclics, Inc. (PCYC), 3D Systems Corporation (DDD): How To Play Them

An analyst upgrade can sometimes be highly useful in allowing you to learn about a new company that might have flown under-the-radar. With the markets trading at all-time highs investors are scrambling to find the best opportunities. In this article I ... [Published InsiderMonkey.com - May 15 2013]

Entities: 3D Systems Corporation, Pharmacyclics Inc, Corning Inc

First reported May 15 2013 - Updated May 15 2013 - 1 reports

Three Value-Presenting Stocks With Upgrades on Monday

Brian is a member of The Motley Fool Blog Network -- entries represent the personal opinion of the blogger and are not formally edited.An analyst upgrade can sometimes be highly useful in allowing you to learn about a new company that might have flown ... [Published Motley Fool - May 15 2013]

Entities: 3D System, Motley Fool, Pharmacyclics Inc, Brian Nichols

Quotes

...chronic lymphocytic leukemia, small lymphocytic lymphoma, and more recently, for Waldenstrm's macroglobulinemia, and mantle cell lymphoma. : "Breakthrough therapy designation is intended to expedite the development and review of drugs for serious or life-threatening conditions. The criteria for breakthrough therapy designation requires preliminary clinical evidence that demonstrates the drug may have substantial improvement on at least one clinically significant endpoint over available therapy. A breakthrough therapy designation conveys all of the fast track program features." The fact that Ibrutinib has obtained breakthrough therapy designation in four different diseases clearly shows the Ibrutinib potential is serious...

Johnson & Johnson's Short-Term Pipeline [Published Seeking Alpha - May 20 2013]

...Jennifer Brown of the Dana-Farber Cancer Institute. "While this research is still early and ongoing, we hope this drug, along with others like it, will lead to prolonged survival and eventually help turn CLL into a condition that is treated like high blood pressure, where a patient can take a couple of pills every day. In the shorter term, these drugs may also provide an alternative to chemotherapy in elderly patients who tend not to tolerate chemotherapy well." Gilead Sciences is already underway with a phase III study of idelalisib in patients with advanced CLL...

ASCO '13 Preview: Gilead's Big Cancer Debut [Published TheStreet.com - May 15 2013]

"Last month we earned a milestone payment of $50 million from our collaboration partner Janssen, for the start of our front line study in CLL and on March 8th we concluded a successful equity offering netting us $201 million. Pharmacyclics remains resolute in its goal to lead in the creation of a new era of patient friendly, body harmonious, medicinal solutions, which are intended to improve the quality of life, increase duration of life and address serious, unmet medical health care needs for patients."

Pharmacyclics Q1 net loss increases [Published Zecco - May 14 2013]

...is the first time in a decade and its first global one ever that the company is indulging in a corporate re-brand ad campaign following recall of "millions of bottles and packages of Tylenol, Benadryl, Motrin and other over-the-counter medicines." One wonders whether the re-branding exercise was needed especially as it carries a risk of reminding customers of the mistakes committed earlier...

Johnson & Johnson: An Investment In A Healthcare Conglomerate That Cannot Go Wrong [Published Seeking Alpha - May 13 2013]

More Content

sort by: Date \| Relevance
2013 FDA Drug Approval Calendar [Published BioPortfolio - May 21 2013]
2013 FDA Drug Approval Calendar [Published Oncology Business Review - May 21 2013]
Pre-Market Analysis on STSI, IPXL, PCYC, and UTHR [Published BayStreet.ca - May 21 2013]
Negative Day, but Strong Technicals [Published Zecco - May 21 2013]
Johnson & Johnson's Short-Term Pipeline [Published Seeking Alpha - May 20 2013]
Pharmacyclics Earnings Review: 19 Days after An... [Published Individual.com - May 20 2013]
PHARMACYCLICS - Ibrutinib - Promising to Delive... [Published TransWorldNews - May 20 2013]
Drivers of M&A in 2013-2016: PI3Ks and BTK Inhi... [Published TransWorldNews - May 20 2013]
Drivers of M&A in 2013-2016: PI3Ks and BTK Inhi... [Published TransWorldNews - May 20 2013]
Ariad Pharmaceuticals, Inc. (ARIA), Infinity Ph... [Published InsiderMonkey.com - May 19 2013]
Pharmacyclics Stock Rating Upgraded by RBC Capi... [Published American Banking News - May 18 2013]
Myriad Genetics Gets a Lift from Angelina Jolie... [Published Equities.com - May 16 2013]
Molecular Diagnostics Market Expected to Grow a... [Published SBWire - May 16 2013]
Global Molecular Diagnostics Market 2012-2016 [Published MarketResearch.com - May 16 2013]
ASCO '13 Preview: Gilead's Big Cancer Debut [Published TheStreet.com - May 15 2013]
ASCO '13 Preview: Roche's Next-Gen Rituxan Step... [Published TheStreet.com - May 15 2013]
Breakthrough Designations Reach 13 [Published I Am Biotech - May 15 2013]
Corning Incorporated (GLW), Pharmacyclics, Inc.... [Published InsiderMonkey.com - May 15 2013]
Three Value-Presenting Stocks With Upgrades on ... [Published Motley Fool - May 15 2013]
Primecap Rides Health to Top Growth Fund [Published Bloomberg - May 15 2013]
Global molecular diagnostics market: 11% CAGR b... [Published MyNewsDesk - May 15 2013]
Another Solid Day For Wall Street [Published Individual.com - May 14 2013]
Pharmacyclics Q1 net loss increases [Published Zecco - May 14 2013]
Very Narrowly Mixed on the Day [Published Zecco - May 14 2013]
3 Biotech Stocks Spiking With Big Volume [Published TheStreet.com - May 13 2013]
Healthcare Review: Pharmacyclics, Alimera Scien... [Published BioMedReports - May 13 2013]
Theravance has the Best Relative Performance in... [Published Comtex SmarTrend - May 13 2013]
Johnson & Johnson: An Investment In A Healthcar... [Published Seeking Alpha - May 13 2013]
N AMERICAN MORNING BRIEFING: Analyst Ratings Ch... [Published TD Ameritrade - May 13 2013]
Pharmacyclics Coverage Initiated at Goldman Sac... [Published American Banking News - May 12 2013]

Blogs

sort by: Date \| Relevance
Breakthrough Designations Reach 13 [Published I Am Biotech - May 15 2013] One of the outcomes of the 2012 Food and Drug Administration Safety and Innovation Act (FDASIA) was the creation of the “Breakthrough Therapy” designation. The new law allows FDA to grant a Breakthrough Therapy designation to drugs showing early clinical ...
2 Winners and 3 Losers from This Week’s Earning... [Published Wall St. Cheat Sheet - May 04 2013] DexCom, Inc. ( NASDAQ:DXCM ) had a loss and beat Wall Street’s expectations, AND beat the revenue expectation. Adjusted Earnings Per Share increased to $-0.16 in the quarter versus EPS of $-0.21 in the year-earlier quarter. Revenue Rose 47.26% to $29.6 ...
Pharmacyclics Earnings: Everything You Must Kno... [Published Wall St. Cheat Sheet - May 02 2013] Pharmacyclics Inc. ( NASDAQ:PCYC ) had a loss and missed Wall Street’s expectations, AND came up short on beating the revenue expectation. The revenue miss is a negative sign to shareholders seeking high growth out of the company. Markets are at 5-year ...
Analysts: Yum Brands Get a Bird Flu Warning and... [Published Wall St. Cheat Sheet - Apr 08 2013] Yum! Brands ( NYSE:YUM ): UBS is reducing its estimates on Yum! Brands to better reflect the uncertainty as a result of the bird flu in China. The firm expects lower sales despite reports that Chinese consumers have reacted less dramatically to each ...
4 Healthcare Stock Stories for Tuesday Investme... [Published Wall St. Cheat Sheet - Mar 26 2013] SanofiAventis ( NYSE: SNY ): Current price $50.50 Sanofi and Transgene have reached a collaboration agreement for the creation of a new state-of-the-art industrial platform focused on the output of immunotherapy products including Transgene’s therapeutic ...

Press Releases

sort by: Date \| Relevance
Pharmacyclics Reports First Quarter 2013 Results [Published PR Newswire: Financial Services - May 01 2013]
Pharmacyclics Announces Date of Financial Resul... [Published PR Newswire: Health - Apr 24 2013]
Research and Markets: Refractory Chronic Lympho... [Published Business Wire - Apr 22 2013]
Pharmacyclics Completes Enrollment of First Pha... [Published PR Newswire: Health - Apr 18 2013]
Research and Markets: Mantle Cell Lymphoma - Pi... [Published Business Wire - Apr 18 2013]